Intellicheck (IDN) Q2 2026 Earnings Call Transcript

Intellicheck (IDN) reported Q2 2026 revenue of $5.9M, up 16% YoY, with net income of $663K, improving from a loss last year. SaaS revenue dominated, and banking/lending grew to 48% of total revenue. Management warned of potential revenue decline in 2026 due to a large customer's multivendor transition. The company expects GAAP profitability for the year and positive adjusted EBITDA in H2 2026.

Original reporting
Published Aug 20, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 12:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Intellicheck (IDN) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$IDNNeutralMed
01

Why it matters

Earnings beat on revenue and profitability but guidance suggests flat FY revenue, creating mixed short‑term outlook.

02

Market read

Micro‑cap earnings with modest numbers; relevance mainly to investors in fintech and identity‑verification space.

03

What to watch

Potential upside from new cargo theft prevention and stadium concessions segments.

Relevance 6/10Novelty 7/10Timing: post‑earnings release Aug 13 2026

Background

Intellicheck, a small Nasdaq‑listed identity‑verification provider, reported Q2 2026 results and forward guidance.

Company-level read

Ticker impact

$IDNNeutralHigh confidence
Context

Q2 2026 earnings released with $5.9M revenue (+16% YoY) and first profit quarter, plus guidance of slightly lower FY revenue.

Expected impact

Potential short‑term pullback on guidance, but upside if diversification succeeds.

Evidence & confidence

New earnings numbers are primary disclosure; guidance lowers expectations, likely pressuring the stock.

Market effects

Highlights growth in identity‑verification SaaS and pressure from large client concentration.

U.S. fintech sector may see increased scrutiny on client diversification.

Limited to niche identity‑verification market; minimal broader impact.

Counterpoint

Guidance of lower FY revenue could be a buying opportunity if diversification materializes.

Key entities

  • Intellicheck, Inc.

    Provider of identity verification SaaS solutions, ticker IDN.

  • Bryan Lewis

    President and CEO of Intellicheck.

Related articles

$IDNMed

Intellicheck Reports Third Quarter 2026 Results

Intellicheck, Inc. (IDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Intellicheck Reports Third Quarter 2026 Results Net Income Rises to $0.5 Million Adjusted EBITDA Increases to $0.9 Million Cash Balance Grows to $13.2 Million, Highest Level Since the End of 2021, with No Debt MELVILLE, NEW YORK – November 12, 2026 – Intellicheck, Inc. (Nasdaq: I

$IDNMed

Intellicheck Reports Second Quarter 2026 Results

Intellicheck, Inc. (IDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Intellicheck Reports Second Quarter 2026 Results Revenue Grows 16% to $5.9 Million Net Income Rises to $0.7 Million Adjusted EBITDA Increases to $1.1 Million MELVILLE, NEW YORK – August 13, 2026 – Intellicheck, Inc. (Nasdaq: IDN) (“Intellicheck” or the “Company”), an industry-lea

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.